Virginia Small Business Financing Authority logo

Virginia Small Business Financing Authority (MEDXF)

Market Closed
11 Dec, 20:00
OTC PINK OTC PINK
$
1. 92
+0.03
+1.75%
$
69.36M Market Cap
3.79 P/E Ratio
0% Div Yield
4,800 Volume
-0.05 Eps
$ 1.89
Previous Close
Day Range
1.87 1.92
Year Range
1.43 3.88
Want to track MEDXF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 60 days

Summary

MEDXF closed yesterday higher at $1.92, an increase of 1.75% from Wednesday's close, completing a monthly decrease of -4.34% or $0.09. Over the past 12 months, MEDXF stock lost -19.75%.
MEDXF is not paying dividends to its shareholders.
The last earnings report, released on Nov 06, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports. The next scheduled earnings report is due on Feb 11, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

MEDXF Chart

Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript

Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript

Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q1 2026 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brendon Buschman - Chief Financial Officer Kenneth d'Entremont - CEO & Director Victoria Rutherford - Corporate Participant Conference Call Participants Andre Uddin - Research Capital Corporation, Research Division Gireesh Seesankar - Bloom Burton & Co., Research Division Michael W. Freeman - Raymond James & Associates, Inc., Research Division Scott Robert Henry - Alliance Global Partners, Research Division Operator Good morning, everyone, and welcome to the Medexus Pharmaceuticals First Quarter 2026 Conference Call.

Seekingalpha | 4 months ago
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript

Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript

Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2025 Earnings Conference Call June 26, 2025 8:00 AM ET Company Participants Brendon Buschman - Chief Financial Officer Kenneth d'Entremont - CEO & Director Conference Call Participants Andre Uddin - Research Capital Corporation, Research Division David C. Martin - Bloom Burton & Co., Research Division Michael W.

Seekingalpha | 5 months ago
Medexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call Transcript

Medexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call Transcript

Medexus Pharmaceuticals, Inc. (OTCQX:MEDXF) Q3 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d'Entremont - CEO Brendon Buschman - CFO Conference Call Participants Michael Freeman - Raymond James David Martin - Bloom Burton Scott Henry - Alliance Global Partners Operator Good morning, everyone. Welcome to the Medexus Pharmaceuticals Third Quarter 2025 Conference Call.

Seekingalpha | 10 months ago

Virginia Small Business Financing Authority (MEDXF) FAQ

What is the stock price today?

The current price is $1.92.

On which exchange is it traded?

Virginia Small Business Financing Authority is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is MEDXF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 69.36M.

When is the next earnings date?

The next earnings report will release on Feb 11, 2026.

Has Virginia Small Business Financing Authority ever had a stock split?

No, there has never been a stock split.

Virginia Small Business Financing Authority Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Kenneth d'Entremont CEO
OTC PINK Exchange
CA58410Q2036 ISIN
CA Country
82 Employees
- Last Dividend
19 Dec 2018 Last Split
- IPO Date

Overview

Medexus Pharmaceuticals Inc. is a distinguished specialty pharmaceutical company operating primarily within Canada and the United States. It dedicates itself to addressing needs in therapeutic areas such as oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Originally known as Pediapharm Inc., the organization underwent a rebranding to Medexus Pharmaceuticals Inc. in December 2018. With its headquarters situated in Toronto, Canada, Medexus is committed to enhancing patient care through the development of innovative medical solutions.

Products and Services

IXINITY: This recombinant factor IX therapeutic is aimed at patients aged 12 years or older with hemophilia B, offering an intravenous solution to manage this bleeding disorder.

Rasuvo and Metoject: Both products represent formulations of methotrexate, tailored to combat rheumatoid arthritis and other auto-immune diseases. These innovative treatments are designed to suppress the immune system to reduce inflammation and tissue damage.

Rupall: This prescription medication addresses the needs of patients suffering from allergies. Rupall represents a next-generation antihistamine designed to provide relief from allergic symptoms with reduced drowsiness.

Gleolan: As an optical imaging agent, Gleolan is indicated for use in patients with glioma. It serves as an adjunct to surgery, enabling the visualization of malignant tissues to improve the accuracy of tumor removal.

Cuvposa: This glycopyrrolate oral solution addresses conditions requiring salivary control, offering patients a means to manage symptoms of chronic conditions that result in excessive salivation.

Naproxen Suspension: Specifically developed for pediatric use, this suspension of naproxen mitigates pain and inflammation, providing relief in various conditions such as juvenile arthritis.

Otixal: Combining ciprofloxacin with flucinolone acetonide, Otixal serves as an effective treatment for bacterial ear infections, offering a dual-action solution to combat infection and inflammation.

Trispan: This injectable suspension of triamcinolone hexacetonide is utilized for its long-acting effect in reducing inflammation in joints, particularly beneficial for patients with chronic joint conditions.

Treosulfan: Part of the preparatory regimen for patients undergoing allogeneic hematopoietic stem cell transplantation, Treosulfan is a bifunctional alkylating agent helping to condition the patient for the transplant procedure.

Over-the-Counter Products: Medexus offers a range of accessible treatments, including Nyda for head lice eradication, Relaxa to address occasional constipation, Oralvisc for joint pain and function improvement in knee osteoarthritis, Tricovel with Biogenina for hair shedding due to Telogen Effluvium, and Calcia products for calcium and vitamin D supplementation.

Contact Information

Address: 35 Nixon Road
Phone: 877 633 3987